Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

被引：0
|
作者：
Reyhaneh Manafi-Farid
Sara Harsini
Bahare Saidi
Hojat Ahmadzadehfar
Ken Herrmann
Alberto Briganti
Jochen Walz
Mohsen Beheshti
机构：
[1] Tehran University of Medical sciences,Research Center for Nuclear Medicine
[2] Universal Scientific Education and Research Network (USERN),Association of Nuclear Medicine and Molecular Imaging (ANMMI)
[3] Klinikum Westfalen,Department of Nuclear Medicine
[4] University Hospital,Department of Nuclear Medicine
[5] Vita-Salute San Raffaele University,Urological Research Institute, Scientific Institute San Raffaele
[6] Institute Paoli-Calmettes Cancer Centre,Department of Urology
[7] Department of Nuclear Medicine & Endocrinology,Division of Molecular Imaging and Theranostics
[8] Paracelsus Medical University,Department of Nuclear Medicine
[9] University Hospital,undefined
[10] RWTH University,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2021年 / 48卷
关键词：
[; Lu]Lu-PSMA; Radioligand therapy; Predictive factors; Response to therapy; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4028 / 4041
页数：13
相关论文
共 50 条
  • [1] Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
    Manafi-Farid, Reyhaneh
    Harsini, Sara
    Saidi, Bahare
    Ahmadzadehfar, Hojat
    Herrmann, Ken
    Briganti, Alberto
    Walz, Jochen
    Beheshti, Mohsen
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (12) : 4028 - 4041
  • [2] Factors predicting the early biochemical response to [177Lu]Lu-PSMA therapy in patients with metastatic castration resistant prostate cancer
    Al-Timimi, Ahmed
    Manafi-Farid, Reyhaneh
    Fallahi, Babak
    Beiki, Davood
    Askari, Emran
    Rezaei, Alireza
    Adinehpour, Zohreh
    Eftekhari, Mohammad
    IRANIAN JOURNAL OF NUCLEAR MEDICINE, 2022, 30 (02): : 115 - 121
  • [3] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Gaertner, Florian C.
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Hauser, Stefan
    Feldmann, Georg
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 312 - 319
  • [4] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Kuerpig, Stefan
    Gaertner, Florian
    Fimmers, Rolf
    Hauser, Stefan
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [5] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, J.
    Eppard, E.
    Kuerpig, S.
    Gaertner, F.
    Fimmers, R.
    Yordanova, A.
    Hauser, S.
    Essler, M.
    Feldmann, G.
    Ahmadzadehfar, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S212 - S213
  • [6] Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Zimbelmann, Stefanie
    Eppard, Elisabeth
    Hauser, Stefan
    Kuerpig, Stefan
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [7] Response to [177Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
    Zisser, Lucia
    Yu, Josef
    Oszwald, Andre
    Wollenweber, Tim
    Kretschmer-Chott, Elisabeth
    Grubmueller, Bernhard
    Kramer, Gero
    Shariat, Shahrokh F.
    Mitterhauser, Markus
    Vraka, Chrysoula
    Hacker, Marcus
    Haug, Alexander R.
    Rasul, Sazan
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (11) : 1113 - 1120
  • [8] Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Kostos, Louise Kathleen
    Lai, William Yu Ching
    Lambroglou, Peter
    Medhurst, Elizabeth
    Buteau, James Patrick
    Sandhu, Shahneen
    Tran, Ben
    Spain, Lavinia Anne
    Conduit, Ciara
    Wallace, Roslyn
    Alipour, Ramin
    Akhurst, Timothy J.
    Kong, Grace
    Cardin, Anthony
    Saghebi, Javad
    Kumar, Aravind Ravi
    Hofman, Michael S.
    Azad, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
    Wojciech Cytawa
    Robin Hendel
    Bartłomiej Tomasik
    Franz-Xaver Weinzierl
    Thorsten Bley
    Jacek Jassem
    Andreas Schirbel
    Andreas K. Buck
    Ralph A. Bundschuh
    Philipp E. Hartrampf
    Rudolf A. Werner
    Constantin Lapa
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 3765 - 3776
  • [10] Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
    Cytawa, Wojciech
    Hendel, Robin
    Tomasik, Bartlomiej
    Weinzierl, Franz-Xaver
    Bley, Thorsten
    Jassem, Jacek
    Schirbel, Andreas
    Buck, Andreas K.
    Bundschuh, Ralph A.
    Hartrampf, Philipp E.
    Werner, Rudolf A.
    Lapa, Constantin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (12) : 3765 - 3776
12345